Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy utilizes **gaseous nitric oxide (NO) generated from atmospheric air via plasma energy devices** and delivered topically (for wound healing) or via inhalation (for systemic conditions). Plasma energy extends the half-life and tissue penetration of NO, enabling effective vasodilatation, angiogenesis, inhibition of platelet aggregation, anti-inflammatory, and antimicrobial activities. Devices such as "Plason" synthesize NO by plasma-chemical methods, producing a cooled NO/plasma stream for clinical use. Primary indications reported include treatment of **chronic, hard-to-heal wounds, sports injuries, acute kidney injury, and pneumonia**. Clinical effects are attributed to increased NO bioactivity in tissue/plasma, enhanced regeneration, inflammation modulation, and improved organ function[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nitric oxide + plasma therapy.